EGFR Mutation-positive Inoperable or Reccrent NSCLC
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Unknown(1)
| Drug | Company |
|---|---|
| dacomitinib hydrate | PFIZER INC (PFE) |
Frequently asked questions
How many drugs are in development for EGFR Mutation-positive Inoperable or Reccrent NSCLC?
BioSniper tracks 1 drug in development for EGFR Mutation-positive Inoperable or Reccrent NSCLC across 1 company.
How many clinical trials target EGFR Mutation-positive Inoperable or Reccrent NSCLC?
There are 1 clinical trial targeting EGFR Mutation-positive Inoperable or Reccrent NSCLC tracked by BioSniper.
Deep-dive into EGFR Mutation-positive Inoperable or Reccrent NSCLC
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis